News | October 27, 2025
Zydus receives approval from Health Canada for Mesalamine suppositories
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
Expanding US operations to address the increased demand for API development and manufacturing
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL
Subscribe To Our Newsletter & Stay Updated
